Lantern Pharma Inc. Reports Significant Clinical Breakthrough in NSCLC Treatment
Lantern Pharma Inc. (NASDAQ: LTRN) has achieved a significant milestone in the treatment of advanced non-small cell lung cancer (NSCLC), with a patient in its Phase 2 HARMONIC(TM) trial achieving a durable complete response. This development is particularly noteworthy as the patient, a 70-year-old never-smoker, had previously failed three lines of therapy, including treatments with […]